Vancouver, BC – March 31, 2015 – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced the appointment of Paul C. Anderson, Ph.D., to its Scientific Advisory Board. Dr. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed.
Dr. Anderson is a synthetic organic chemist by training with more than 30 years of experience in pharmaceutical research and development. Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and in more than 20 years with the company, held positions of increasing responsibility in the research organization including more than 12 years as head of the Boehringer Ingelheim research centers in Canada and in the United States. While in Canada, Dr. Anderson and his team introduced several anti-viral drugs into pre-clinical and clinical development, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into pre-clinical development. He received his Ph.D. in organic chemistry at the University of Alberta.
Mr. Anderson is also a Consultant for the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN).
“We are delighted to have Paul join our Scientific Advisory Board. Paul brings exceptional medicinal chemistry expertise and vast experience in drug discovery research in several therapeutic areas like CNS, immunology & inflammation and metabolic diseases,” said Craig Schneider, President and CEO of InMed.
In addition, InMed announced the appointment of Dr. Sazzad Hossain to its Board of Directors. Dr. Hossain is the current Chief Scientific Officer of InMed and a co-founder of the company. He developed the “IDP” drug discovery platform and is leading all R&D activities of InMed Pharmaceuticals.
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the Company.
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
President and Chief Executive Officer
[email protected] / www.inmedpharma.com
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
Amy Wheeler (Media)
Forward Looking Statements
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such “forward-looking statements” involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: the exemption may be removed or become no longer applicable; anticipated clinical studies may not be conducted as planned, or at all; and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.